MaxQ AI has announced a new distribution agreement with EnvoyAI, a subsidiary of TeraRecon, that will make its Accipio intracranial hemorrhage (ICH) platform available through the EnvoyAI Exchange marketplace.

The platform includes numerous solutions, including the Accipio Ix ICH identification software that received clearance from the FDA back in November. According to MaxQ AI, it will work alongside TeraRecon’s Northstar AI Results Explorer to provide users with “powerful first-of-kind physician workflows for ICH that are unmatched in radiology today.”

“Our agreement with EnvoyAI will enable hospitals around the world to have access to our revolutionary AI-enabled Accipio platform for approved commercial use in their emergency rooms and for clinical research purposes,” Chris Schnee, senior vice president of commercial operations for MaxQ AI, said in a prepared statement. “This partnership further accelerates the adoption of MaxQ solutions by acute care hospitals, which are TeraRecon's core customer base. We are proud to be collaborating commercially with a market share leader in radiology advanced visualization.”

“We believe strongly in this concept of augmented intelligence, whereby the physician remains in control, interpretations are better informed and workflow is accelerated simultaneously,” Jeff Sorenson, president and CEO of TeraRecon, said in the same statement. “Our Northstar AI Results Explorer™ plays a pivotal role in allowing physicians to consume Accipio Ix results in many different ways, while always respecting the physician's preferences and belief system.”